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MaDespite therapeutic advances, acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality
worldwide. One potential limitation of the current treatment paradigm is the lack of effective therapies to optimize
reperfusion after ischemia and prevent reperfusion-mediated injury. Experimental studies indicate that this process
accounts for up to 50% of the ﬁnal infarct size, lending it importance as a potential target for cardioprotection. However,
multiple therapeutic approaches have shown potential in pre-clinical and early phase trials but a paucity of clear clinical
beneﬁt when expanded to larger studies. Here we explore this history of trials and errors of the studies of cyclosporine A
and other mitochondrial membrane permeability inhibitors, agents that appeared to have a promising pre-clinical record
yet provided disappointing results in phase III clinical trials. (J Am Coll Cardiol Basic Trans Science 2016;1:524–35)
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access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).D espite therapeutic advances, acute myocar-dial infarction (AMI) remains a leading causeof morbidity and mortality worldwide. Sus-
tained research efforts over the years have achieved
numerous milestones (1–3). Despite the success
stories, the rate of progression to heart failure and
related complications remains unacceptably high
(3,4). One potential limitation is the lack of effective
therapies to optimize reperfusion after ischemia and
prevent reperfusion-mediated injury. This has been
termed reperfusion injury, or alternatively ischemia-
reperfusion injury (5). Experimental studies indicate
that this process accounts for up to 50% of the ﬁnal
infarct size, lending it importance as a potential target
for cardioprotection (6). However, multiple therapeu-
tic approaches have failed to translate from the bench
to the bedside, or have shown therapeutic potential
in early phase II trials (7–9) but have failed to translatem the aDivision of Cardiology, VCU Pauley Heart Center, Virginia Commo
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REPERFUSION INJURY
The phenomenon of reperfusion injury was ﬁrst born
out of a demonstration that post-ischemic restoration
of blood ﬂow had several potential deleterious ef-
fects, including myocardial stunning (13). The idea of
harm from reperfusion was later supported by
demonstration of smaller infarct size with slower,
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AB BR E V I A T I O N S
AND ACRONYM S
AMI = acute myocardial
infarction
CsA = cyclosporine A
IMM = inner mitochondrial
membrane
mPTP = mitochondrial
permeability transition pore
PCI = percutaneous coronary
intervention
= reactive oxygen species
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525reperfusion at normal pressure, a beneﬁt gained from
interventions applied after the ischemic period rather
than within it (14).
During ischemia, intracellular Naþ and Caþþ accu-
mulate as downstream results of acidosis from
anaerobic glycolysis, ultimately reaching a Caþþ-
overloaded state. Upon reperfusion, the rapid
normalization of pH causes uncontrolled myocyte
contraction, intracellular edema, and formation of
reactive oxygen species (ROS) (15). Within the context
of reperfusion injury, perhaps the most salient
component of this process occurs at the inner mito-
chondrial membrane (IMM). The IMM remains closed
throughout ischemia but undergoes an abrupt tran-
sition in permeability during reperfusion (16), which
collapses the membrane potential and uncouples
oxidative phosphorylation (17). As a result, there is
increased inorganic phosphate concentration,
increased Caþþ ﬂux, and mitochondrial edema, ulti-
mately leading to the cytoplasmic release of cyto-
chrome C, a proapoptotic protein that activates
caspase-3 and leads to the death of the cardiac
myocyte (5,6,15,18) (Figure 1).
The biochemical liaison for the increased leakage
of the IMM is the mitochondrial permeability transi-
tion pore (mPTP). Much remains to be understood
about the mPTP, but a leading hypothesis holds that
the mPTP forms from F-type adenosine triphosphate
synthase dimers within the lipid bilayer of the IMM
(19). The channel opens and is forced to remain open
in response to high concentrations of calcium, inor-
ganic phosphate, and ROS, or with reduced IMM po-
tential. All of these conditions are active during
myocardial ischemia and reperfusion (20).
Many other signaling cascades and processes
within and outside the mitochondria are concomi-
tantly activated during ischemia and reperfusion and
are likely to contribute to infarct size. For the scope of
this review, we focused only on the mechanisms
involving a change in permeability in the mitochon-
drial membrane for which a drug had been tested in
both pre-clinical and clinical studies.
ISCHEMIC PRE-CONDITIONING
This discovery that reperfusion could be a double-
edged sword (13) spawned a new wave of experi-
ments. One landmark study described how repeating
cycles of alternating ischemia and reperfusion per-
formed prior to prolonged coronary artery occlusion
signiﬁcantly reduced ﬁnal infarct size in dogs (even
when total ischemia time was longer); this created the
new ﬁeld of “pre-conditioning” (21), replicated in
numerous laboratories around the world (22–24).A “second window” of cardioprotection was
also shown to begin 24 h after the initial win-
dow of protection. In 1 study, infarct size was
reduced in rabbits subjected to four 5-min cy-
cles of coronary artery occlusion prior to 24-h
recovery, followed by a 30-min reocclusion
(25) or a 90-min reocclusion (26). The clinical
translational value of having identiﬁed the
second window of cardioprotection, however,
is still uncertain.
Interestingly, limitations of the pre-
conditioning strategy became apparent quite
rapidly. Cardiac protection was seen when occlusion/
reperfusion cycles were performed prior to 40- or 60-
min occlusion, but not prior to 90- (27) or 180-min (21)
occlusion. These experiments highlight that the efﬁ-
cacy of pre-conditioning is limited to a speciﬁc win-
dow of duration of ischemia. Hence the difﬁculty in
translation to humans: it is difﬁcult to determine
exactly when a patient starts experiencing ischemia,
and usually by the time the patient is seen in the
hospital, the ischemia has been ongoing for hours.
ISCHEMIC POST-CONDITIONING
An additional step forward in the ﬁeld was provided
by the demonstration of protective effects of in-
terventions applied after the ischemia and the initial
reperfusion: “post-conditioning.” Brief serial epi-
sodes of controlled reperfusion interrupted by
repeated brief bursts of ischemia reduced ﬁnal infarct
size: 3 cycles of 30 s of reperfusion alternating with
30 s of occlusion (for a total of 3 min), after 60 min of
ischemia due to coronary occlusion provided a sig-
niﬁcant reduction in infarct size in dogs by 30% to
40% (28). The ﬁnding of beneﬁcial effects of condi-
tioning being applied after reperfusion provided an
intense stimulus to the ﬁeld, as it suggested a time
window for intervention that extended beyond
reperfusion. The same studies, however, also high-
lighted the critical time dependency of these ap-
proaches. Post-conditioning as means of controlled
reperfusion intermittently interrupted by brief
ischemia is effective in reducing infarct size if initi-
ated within seconds of reperfusion (29,30) while
failing to reduce infarct size if post-conditioning is
delayed by more than 1 min (30,31). These consider-
ations may explain the challenge of translating into
clinical beneﬁts in recent clinical trials (32).
PHARMACOLOGIC ISCHEMIC CONDITIONING
The study of the events occurring in ischemic pre- and
post-conditioning has stimulated a large number of
investigations into the signaling and mechanisms.
ROS
FIGURE 1 Schematic Representation of the Therapeutic Target of the
Mitochondrial Membrane Permeability Inhibitors
Ischemia and reperfusion lead to Caþþ overload and reactive oxygen species (ROS)
formation leading to opening of the mitochondrial permeability transition pore (mPTP),
cytochrome C (Cyt C) release into the cytoplasm, caspase-3 activation, and cell death.
Cyclosporine, MTP-131, and TRO40303 inhibit mitochondrial membrane permeability and
prevent cell death. mPTP ¼ mitochondrial permeability transition pore.
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ing but also insight into potential therapeutic targets.
The hypothesis that a drug given at a speciﬁc time
during reperfusion could reduce infarct size and
improve on the beneﬁt of reperfusion became the
search for the “holy grail” in cardiology (6). For the
purpose of this review, we will focus on CsA and other
drugs targeted at inhibiting the permeability of the
mitochondrial membrane during ischemia and reper-
fusion. CsA and other drugs with similar mechanism
had shownpromising pre-clinical data,whichwas then
studied in phase II and III clinical trials.
PRECLINICAL STUDIES OF CSA
Finding a targeted medication that could be given
during a speciﬁc time during ischemia or reperfusion,
in an effort to reduce infarct size, become the goal of
many therapeutic attempts (6). CsA is a cyclic non-
ribosomal peptide that was ﬁrst extracted from the
Norwegian soil fungus Tolypociadium inﬂatum in
1969 (33,34). It is used as an immune suppressant in
solid-organ transplant patients, serving as a calci-
neurin inhibitor in T-cell lymphocytes (35), though
experimental studies conducted in the late 1980sidentiﬁed CsA also as an inhibitor of mPTP opening
(36). A study on isolated perfused rat hearts revealed
that treatment with CsA conferred cardioprotection
in myocardial ischemia-reperfusion experiments: CsA
0.2 mM infused during ischemia restored the ATP/
adenosine diphosphate ratio and adenosine mono-
phosphate content to pre-ischemic levels and partially
improved left ventricular diastolic pressure (37).
The effects of CsA, however, were exquisitely dose
dependent; concentrations either lower (0.1 mM) or
higher (0.4 to 1.0 mM) had no protective effects (37).
The threshold dose effect at 0.2 mM was conﬁrmed in
other studies, and reduced efﬁcacy at higher concen-
trations was shown (37,38). In vivo studies using
weight-based dosing showed protective effects for CsA
doses of 2.5 mg/kg but not 1.0 mg/kg; effectiveness for
doses of 5.0 mg/kg or greater was seen in some but not
all experimental studies in rodents (39–41).
Moreover, the effects of CsA appear to be time
dependent. When given before ischemia onset (42) or
15 min prior to reperfusion (43), CsA 10 mg/kg pro-
vided powerful cardioprotection; however, when
given 7 min (44), 5 min (42), 3 min (45), or 2 min (46)
prior to reperfusion, this cardioprotection was no
longer provided. This time-dependent effect mirrors
ischemic post-conditioning results (30,31).
Table 1 summarizes pre-clinical studies with CsA.
PILOT PHASE II CLINICAL TRIALS OF CSA
In 2008, Piot et al. (47) published the results of the
ﬁrst pilot single-blind phase II clinical trial in patients
with ST-segment elevation myocardial infarction
(STEMI) (47). Fifty-eight patients were randomized to
either 2.5 mg/kg intravenous CsA (Sandimmune,
Novartis, Basel, Switzerland) or matching placebo
given “less than 10 min before direct stenting,” and a
reduction of infarct size by the area under the curve
for creatine kinase was demonstrated (Figure 2),
although this reduction was not closely mirrored by
the cardiac-speciﬁc troponin I area under the curve.
Total ischemic time was approximately 5 h in each
group, but, unfortunately, the exact time between
study medication administration and stenting for
each group was not reported. Indeed, the single-blind
design allows for the possibility of bias (e.g., opera-
tors could have been more likely to wait longer be-
tween CsA administration and reperfusion to allow
for drug steady state). A subgroup of patients (n ¼ 27)
underwent cardiac magnetic resonance 5 days after
AMI, revealing a smaller infarct size in those who
received CsA (Figure 2). There were no signiﬁcant
differences in adverse clinical events between the 2
groups (47).
TABLE 1 Preclinical Studies of Mitochondrial Membrane Permeability Inhibitors in AMI
Animal Model Dose Timing Effects on Infarct Size Other Notes
Cyclosporine A
Nazareth et al.,
1991 (38)
Rat
(ex vivo)
Ischemia (60 min) and
reperfusion (10 min)
Variable At start of incubation N/A 0.2 mM inhibited ATP loss;
higher doses reversed this
effect
Grifﬁths and
Halestrap,
1993 (37)
Rat
(ex vivo)
Ischemia (30 min) and
reperfusion (15 min)
0.2 mM 2 min prior to ischemia N/A Demonstrated both lower and
higher doses of CsA to be
less effective
Gomez et al.,
2007 (40)
Mouse Ischemia (25 min) and
reperfusion (24 h or
30 days)
10 mg/kg 5 min prior to reperfusion Reduced by w50% LVEF signiﬁcantly improved and
30-day mortality reduced
Dow and Kloner,
2007 (46)
Rat Ischemia (30 min) and
reperfusion (120 min)
5 mg/kg, 10 mg/kg w2 min prior to reperfusion No signiﬁcant change Post-conditioning also did not
reduce infarct size in this
study
Pagel and
Krolikowski,
2009 (41)
Rabbit Ischemia (30 min) and
reperfusion (180 min)
5 mg/kg 2 min prior to reperfusion No signiﬁcant change
when used alone
Beneﬁt when combined with
helium and alkalosis pre-
conditioning, uncertain
signiﬁcance
Karlsson et al.,
2010 (45)
Pig Ischemia (45 min) and
reperfusion (120 min)
10 mg/kg “for 3 minutes before
reperfusion”
No signiﬁcant change Data suggest possible
deleterious interaction
between CsA and isoﬂurane
Karlsson et al.,
2012 (44)
Pig Ischemia (40 min) and
reperfusion (240 min)
2.5 mg/kg 7 min prior to reperfusion No signiﬁcant change Closed-chest model
De Paulis et al.,
2013 (42)
Rat Ischemia (30 min) and
reperfusion (120 min)
10 mg/kg 10 min prior to ischemia or
5 min prior to reperfusion
Reduced by >50% if
given pre-ischemia;
no signiﬁcant change
pre-reperfusion
Highlights potential beneﬁt in
combined action on
cyclophilin D and complex I
(isoﬂurane)
Huang et al.,
2014 (39)
Rat Ischemia (30 min) and
reperfusion (120 min)
1 mg/kg, 2.5 mg/kg,
5 mg/kg
Not reported 2.5 mg/kg and 5 mg/kg
reduced infarct size
Difﬁcult to interpret without
administration times
reported
Zalewski et al.,
2015 (43)
Pig Ischemia (60 min) and
reperfusion (180 min)
10 mg/kg Between 15 min and 10 min
prior to reperfusion
Reduced by 14% CsA also improved myocardial
blood ﬂow and LVEF
TRO40303
Schaller et al.,
2010 (54)
Rat Ischemia (35 min) and
reperfusion (24 h)
0.5 mg/kg, 1.25 mg/kg,
2.5 mg/kg
3 min infusion starting 10 min
prior to reperfusion
2.5 mg/kg reduced by
38%, lower doses not
active
TRO40303 delayed mPTP
opening but did not affect
Ca2þ retention capacity
Le Lamer et al.,
2014 (55)
Rat Ischemia (35 min) and
reperfusion (24 h)
0.3 mg/kg, 1.0 mg/kg,
3.0 mg/kg,
10.0 mg/kg
10 min before ischemia,
10 min before reperfusion, or
10 min after reperfusion
1–10 mg/kg pre-
reperfusion doses
reduced by 40%–50%,
1 mg/kg pre-ischemia
reduced by 55%
Separate study established
safety and pharmacokinetic
data in phase I study in
humans
MTP-131
Cho et al., 2007
(57)
Rat Ischemia (60 min) and
reperfusion (60 min)
3 mg/kg 30 min prior to ischemia,
repeated 5 min prior to
reperfusion
Reduced by 10% Arrhythmias were less frequent
and less severe in the
treatment arm
Kloner et al.,
2012 (59)
Sheep Ischemia (60 min) and
reperfusion (180 min)
0.05 mg/kg/h 210 min infusion starting
30 min prior to
reperfusion
Infarct size reduced by
15%
Relative infarct size reductions
more prominent in larger
infarcts, consistently across
all models.
Guinea
pig
(ex vivo)
Ischemia (20 min) and
reperfusion (2 h)
1 nM 10 min prior to ischemia and
“at onset” of reperfusion
Infarct size reduced by
38%–42%
Rabbit Ischemia (30 min) and
reperfusion (180 min)
0.05–0.10 mg/kg/h 200 min infusion starting
1 min, 10 min, or
20 min prior to
reperfusion.
No signiﬁcant reduction in
infarct size.
Sloan et al., 2012
(58)
Rat
(ex vivo)
Ischemia (20 min) and
reperfusion (120 min)
1 nM At onset of reperfusion Reduced by w30% Greater reduction in infarct size
in diabetic rats
Brown et al.,
2014 (60)
Rabbit Ischemia (30 min) and
reperfusion (3 h)
0.05 mg/kg/h 60 min or 180 min infusion
starting 20 min prior to
reperfusion
Reduced by 40%–50% Negative results when infusion
started 10 min after
reperfusion.
Guinea
pig
(ex vivo)
Ischemia (20 min) and
reperfusion (2 h)
1 nM “Beginning at the onset of
reperfusion”
Reduced by 40%–50%
AMI ¼ acute myocardial infarction; ATP ¼ adenosine triphosphate; CsA ¼ cyclosporine A; LVEF ¼ left ventricular ejection fraction; mPTP ¼ mitochondrial permeability transition pore.
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528In a phase II double-blinded clinical trial of 101
patients with STEMI treated with ﬁbrinolysis, CsA 2.5
mg/kg administered immediately before ﬁbrinolysis
did not demonstrate any appreciable beneﬁt over
placebo with regard to infarct size (measured with
biomarkers), left ventricular ejection fraction, or
outcomes (48).
In a clinical trial of 61 patients undergoing elective
aortic valve surgery, CsA 2.5 mg/kg given 10 min
before aortic cross-clamp removal signiﬁcantly
reduced myocardial injury measured as area under
the curve for cardiac troponin I (49). Similarly, in a
trial of 78 patients undergoing coronary artery bypass
grafting surgery, CsA 2.5 mg/kg given before aorta
cross clamping (before ischemia) reduced myocardial
injury, especially in patients with longer ischemic
times (50).
The CYCLE (CYCLosporinE A in Reperfused Acute
Myocardial Infarction) trial further tested CsA in a
larger randomized phase II open-label study,
enrolling 410 patients presenting with STEMI, within
6 h of symptom onset and with angiographic evidence
of Thrombolysis In Myocardial Infarction ﬂow
grade #1 in any epicardial coronary artery (51). Sub-
jects were randomized to receive a bolus of intrave-
nous CsA 2.5 mg/kg (n ¼ 207) “at least 5 min before
percutaneous coronary intervention” versus no
treatment (n ¼ 203). The exact time incurred from
CsA treatment to reperfusion (delay) was not given.
Being an open-label study, it is reasonable to assume
that patients incurred no delay in the no-treatment
arm, better described as a no-treatment or no-delay
arm. A PROBE (Prospective Randomized Open Blin-
ded Endpoint) design was employed, in which elec-
trocardiographic tracings and angiogram recordings
were centrally assessed by blinded readers. Ulti-
mately treatment with CsA had no effect on the
primary endpoint of interest, >70% resolution of ST-
segment elevation on electrocardiography 60 min
after restoring ﬂow to the culprit vessel (Figure 2), or
secondary endpoints (biochemical infarct size
(Figure 2), left ventricular remodeling by echocardi-
ography, or relevant clinical outcomes 6 months after
reperfusion. Mean ischemic time in this cohort was
approximately 3 h (51). Whether extending ischemia
time by 5 min in the CsA treatment arm may have
potentially negatively impacted outcomes is
unknown.
The inconsistencies in the effects of CsA in the
phase II clinical trials are difﬁcult to reconcile. How-
ever, a trend may be noted: as seen in the pre-clinical
studies, earlier treatment with CsA, such as before
ischemia onset (50) or 10 min before reperfusion
(47,49) appeared to provide more favorable resultsthan those in which CsA was given 5 min prior to
reperfusion (51) or immediately after. Table 2 sum-
marizes clinical studies with CsA.
PHASE III CLINICAL TRIAL OF CsA IN STEMI
The CIRCUS (Cyclosporine to ImpRove Clinical
oUtcome in ST-elevation myocardial infarction pa-
tients) trial was a multicenter, double-blinded, ran-
domized phase III clinical trial comparing CsA with
placebo in 970 patients presenting with STEMI and
angiographically documented occlusion of the left
anterior descending artery undergoing percutaneous
coronary intervention (PCI) (52). CsA or matched
placebo infusion was given “over 2–3 minutes.
before the PCI procedure” (52,53). Average ischemic
time was approximately 4.5 h in both arms. Again,
there was no difference in the composite primary
endpoint (all-cause mortality, worsening heart failure
during initial hospitalization, rehospitalization for
heart failure, or adverse left ventricular remodeling
within 1 year of the event) (Figure 2) or secondary
endpoints (individual components of the composite
endpoint, change in left ventricular ejection fraction
after 1 year, recurrent AMI, new cerebrovascular ac-
cident, or unstable angina). Moreover, CsA failed to
reduce ST-segment elevation or reduce infarct size by
biochemical criteria (52).
The results of the CIRCUS study are in line with
those of the CYCLE phase II trial (51) but inconsistent
with those of the ﬁrst phase II STEMI study (47). The
CIRCUS trial used a different formulation of CsA than
the original study, but the CYCLE trial used the same
formulation of the ﬁrst pilot study, thus making it
unlikely that the formulation affected outcomes. A
signiﬁcant difference in trial designs is evident in the
timing of CsA treatment, with “less than 10 minutes
prior to direct stenting” in the ﬁrst phase II study to
“in the minutes preceding PCI” in the CIRCUS trial,
and approximately 5 min in the CYCLE study,
possibly affecting the effectiveness of CsA (52,53).
Figure 3 shows the effects of timing on CsA efﬁcacy in
pre-clinical and clinical trials.
TRO40303: AN INHIBITOR OF THE
MITOCHONDRIAL PERMEABILITY
TRANSITION PORE
A recently explored compound is TRO40303, which
acts on the mPTP by binding translocator protein 18
kDa, an outer mitochondrial membrane protein that
interacts with proteins implicated in mPTP formation
(54). In a pre-clinical study in rats of myocardial
ischemia (35 min), TRO40303 2.5 mg/kg given 10 min
FIGURE 2 Results of Clinical Trials With CsA in Acute Myocardial Infarction
(A, B) Results of a small phase II clinical trial of cyclosporine A (CsA) in ST-segment elevation myocardial infarction (47): CsA led to a small but statistically signiﬁcant
(p ¼ 0.04) reduction in infarct size measured as plasma creatine kinase (CK) levels over time and as delayed gadolinium enhancement at cardiac magnetic resonance
in a subgroup of patients. (C, D) Lack of beneﬁt of CsA in the open-label phase II CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial (51). (E, F) Lack
of clinical beneﬁt of CsA in the double-blind CIRCUS (Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients) clinical trial (52) in
terms of clinical outcomes and surrogate endpoints such as plasma CK levels and resolution of ST-segment elevation. hs-cTnT ¼ high-sensitivity cardiac troponin T;
IU ¼ international units; PCI ¼ percutaneous coronary intervention; Q ¼ quartile.
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TABLE 2 Clinical Trials of Mitochondrial Membrane Permeability Inhibitors in AMI
Clinical Indication
Inclusion Criteria
(Selected) Dose Timing Effects on Infarct Size Other Notes
Cyclosporine A
Piot et al., 2008 (47)
Single-blind RCT
STEMI
N ¼ 58
1) Anterior STEMI
2) TIMI ﬂow grade <1
3) Slated for PCI
(primary or rescue)
2.5 mg/kg “less than 10 minutes”
prior to reperfusion
40% reduction in
AUC for CK
20% reduction in
infarct size by
cardiac MRI
A 1-year follow-up in a
subcohort found
more favorable
cardiac remodeling
at cardiac MRI
Ghaffari et al., 2013 (48)
Double-blind RCT
STEMI
N ¼ 101
1) Anterior STEMI
2) Candidate for
thrombolytic therapy
2.5 mg/kg “immediately” prior to
reperfusion
No difference in
CK-MB or
troponin I
No effects on clinical
outcomes
Chiari et al., 2014 (49)
Single-blind RCT
Scheduled for
aortic valve
surgery
N ¼ 61
1) Age >18 yrs
2) Scheduled for aortic
valve surgery
2.5 mg/kg “less than 10 minutes”
prior to aortic
unclamping
35% reduction
AUC for cardiac
troponin I
Beneﬁcial effect
remained signiﬁcant
after adjustment for
cross-clamping
duration
Hausenloy et al., 2014 (50)
Double-blind RCT
Referred for
elective
CABG surgery
N ¼ 78
1) Adult
2) Referred for elective
CABG surgery
2.5 mg/kg Prior to cross-clamping of
the aorta
38% reduction in
AUC for cardiac
troponin T
Beneﬁcial effect was
optimized in
patients with longer
ischemic times
CYCLE51 (2016) (51)
Open label RCT with PROBE
design
STEMI
N ¼ 410
1) First STEMI
2) TIMI ﬂow grade <2
3) Slated for PCI
4) Within 4–6 h of onset
of chest pain
2.5 mg/kg “at least 5 min” prior to
reperfusion
No difference in
ST-segment
normalization or
cardiac troponin T
at day 4
No effects on cardiac
remodeling
No effects on clinical
outcomes
CIRCUS52 (2015) (52)
Double-blind RCT
STEMI
N ¼ 791
1) Anterior STEMI
2) TIMI ﬂow grade <1
in LAD
3) Slated for PCI
2.5 mg/kg “prior to PCI” No difference in
peak CK
No effects on clinical
outcomes
TRO40303
MITOCARE56 (2015) (56)
Double-blind RCT
STEMI
N ¼ 163
1) First STEMI
2) TIMI ﬂow grade <1
3) Slated for PCI
6 mg/kg “15 min (and preferably 5
min)” prior to
reperfusion
No difference in AUC
for CK or cardiac
troponin I over 3
days
No effects on cardiac
remodeling
No effects on clinical
outcomes
MTP-131
EMBRACE-STEMI61
(2016) (61)
Double-blind RCT
STEMI
N ¼ 297
1) First anterior STEMI
2) TIMI ﬂow grade <1
3) Slated for PCI
0.1 mg/kg/h $15 min but <60 min and
for 1 h following
reperfusion
No difference in
AUC for CK or
cardiac troponin I
over 3 days
No effects on cardiac
remodeling
No effects on clinical
outcomes
AUC ¼ area under the curve; CABG ¼ coronary artery bypass grafting; CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band; LAD ¼ left anterior descending artery; MRI ¼ magnetic resonance
imaging; PCI ¼ percutaneous coronary intervention; PROBE ¼ prospective open blinded endpoint; RCT ¼ randomized controlled trial; STEMI ¼ ST-segment elevation myocardial infarction;
TIMI ¼ Thrombolysis In Myocardial Infarction.
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530prior to reperfusion signiﬁcantly reduced infarct size
(54). Further work with the rat model demonstrated
increased infarct size sparing with higher doses of the
agent, which was beneﬁcial if given before ischemia
onset or 10 min prior to reperfusion but not if given
after reperfusion; the same investigators executed a
phase I trial in healthy subjects to obtain pharmaco-
kinetic and favorable safety data as part of the overall
translational process (55).
The MITOCARE trial was a proof-of-concept
double-blinded study, which investigated TRO40303
6 mg/kg administered after coronary angiography but
before balloon inﬂation during PCI in patients with
acute STEMI (56). The exact timing from treatment to
reperfusion is not reported, but, given the double-
blinded nature of the study, is unlikely to have been
signiﬁcantly delayed, considering the fact that oper-
ators would have striven for the earliest possiblereperfusion for each subject in case they were ran-
domized to placebo. TRO40303 provided no
cardioprotection as measured by biomarker release
over 3 days, cardiac magnetic resonance–assessed
myocardial salvage index, infarct size, or left ven-
tricular ejection fraction (56). Again, it is reasonable
to think this seemingly disconnect between pre-
clinical and clinical trials might have been due to
the lack of pretreatment in the latter case, with or
without other factors (e.g., differences in equivalent
doses between species).
MTP-131: AN INHIBITOR OF THE INTERNAL
MITOCHONDRIAL MEMBRANE PERMEABILITY
Another attempt at mitochondrial blockade came
recently in the form of MTP-131, 1 of a class of many
newly developed small peptides found to target the
FIGURE 3 Timeline in Preclinical and Clinical Trials
A
B
Schematic representation of time-dependent effects of (A) cyclosporine A (CsA) and (B) MTP-131 and TRO40303 in pre-clinical and
clinical trials.
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531internal mitochondrial membrane and reduce ROS
production in response to multiple chemical
stressors. When infused prior to the onset of ischemia
and repeated 5 min prior to reperfusion in an in vivo
rat model, infarct size showed a 10% reduction (57);isolated rat heart studies later suggested an infarct-
sparing effect when infused at the time of reperfu-
sion after being subjected to 20 min of global
ischemia (58). Using this agent, infarct size was also
reduced in the sheep model when infused after
TABLE 3 Characteristics of the Ideal Drug for Clinical Translation in Myocardial Reperfusion Injury
Ideal Drug Cyclosporine A
Preclinical studies
MoA Single known target Inhibition of mPTP and of calcineurin
Dose-response relationship Linear response Inconsistent response, possibly U-shaped
Toxicity Limited or none Toxic at high doses
Therapeutic index Large Narrow
Therapeutic window Effective when given before, at or after reperfusion Efﬁcacy appears limited when given <10 min
prior to reperfusion
Efﬁcacy across different experimental
settings
Exploring longer duration of ischemia and of
reperfusion
Limited data
Effects on infarct sparing Use of at least 2 different independent
methodologies
Consistent reduction seen with multiple methods
Effects on cardiac remodeling Measure of cardiac dimensions and systolic/diastolic
function
Preservation of cardiac systolic function
Sufﬁcient length of follow-up Sufﬁcient to see to full effects on infarct healing
and remodeling
Limited data
Validation in 2 or more animal species Validated in rodents and large animals Validated in rodents and large animals
Class effect Validation of the MoA using genetically modiﬁed
mice or additional drugs
Validation was found in the mice lacking
cyclophylin D and with mPTP inhibitors
Efﬁcacy in animals of both sex Necessary Limited data
Efﬁcacy in animal models of aging or
metabolic impairment
Older animals or models of obesity or diabetes None available
Clinical studies
Toxicity in phase I clinical trials No or limited toxicity Signiﬁcant dose-dependent toxicity
Design of phase II clinical trials Double-blinded, random allocation Variable design (open label, single blind, double
blind), random allocation
Efﬁcacy in phase II clinical trials Efﬁcacy established on all surrogate endpoints,
favorable signal toward reduction of clinical
endpoints, no unanticipated adverse events
Discordant results of phase II clinical trials
MoA ¼ mechanism of action; mPTP ¼ mitochondrial permeability transition pore.
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532ischemia onset (60 min of ischemia, with MTP-131
infusion initiated 30 min prior to reperfusion), but
no beneﬁt was seen in the rabbit models (total 30 min
of ischemia, with MTP-131 infusion initiated 20 min,
10 min, or 1 min prior to reperfusion) (59). This was
contradicted by positive results in later rabbit models
where MTP-131 was infused either prior to 180 min of
ischemia or 20 min prior to reperfusion (60).
The EMBRACE-STEMI (Evaluation of Myocardial
Effects of Bendavia for Reducing Reperfusion Injury
in Patients With Acute Coronary Events-ST-Segment
Elevation MI) clinical trial was a phase II clinical trial
including 297 patients with ST-segment elevation
myocardial infarction, designed with a pre-speciﬁed per-
protocol primary analysis that had strict timing criteria
that excluded from the analysis those patients who did
not begin the infusion of MTP-131 at least 10 min prior to
PCI or who did not receive infusion for at least 45 min
after PCI (n ¼ 118). MTP-131 failed to meet its primary
endpoint in a reduction in infarct size by biochemical
analysis. The reasons for the lack of beneﬁt are not clear;
possibly the interval of 10 min prior to PCI was insufﬁ-
ciently long to guarantee full activity of the inhibitor at
time of reperfusion. Of note, over 60% of the enrolledand treated subjects were excluded from the primary
analysis, most of them due to pre-PCI TIMI ﬂow grade >1
or other exclusion criteria (61).
CSA AND THE “Ideal DRUG” FOR
BENCH-TO-BEDSIDE TRANSLATION
The lack of beneﬁt of CsA in the CIRCUS trial has
brought into question not only the value of CsA as a
therapy for AMI, but the entire process of bench-to-
bedside translational research (62) and the value of
pilot phase II clinical trials (63). As such, it is worth
discussing what constitutes the ideal drug for clinical
translation and reviewing whether CsA ﬁts that
proﬁle (Table 3).
It is indeed apparent that CsA given as a single
dose of 2.5 to 10 mg/kg intravenously 10 to 15 min
prior to reperfusion in animal models signiﬁcantly
reduces infarct size, preserving functional myocar-
dium and global systolic function (37,40,43). As such,
the phase II pilot study published in 2008 was able to
largely reproduce the beneﬁts of CsA in patients with
STEMI by administering the drug up to 10 min prior to
reperfusion with direct stenting (47). It is worth
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533considering, once again, the 2 different scenarios that
may have occurred in this single-blinded study: 1)
direct stenting could have been delayed by 10 min
only in the CsA group without delaying reperfusion
for any amount of time in the control group (possibly
because considered unethical); or a less likely sce-
nario in which 2) direct stenting was delayed also in
the control group, which would have introduced
harm to the control group while favoring the CsA
group.
Pre-clinical studies with CsA in AMI, however,
have inconsistently shown a reduction in infarct size
and, in particular, have shown a limited effect when
CsA is given <10 min prior to reperfusion. In the
open-label CYCLE study, CsA treatment was given at
least 5 min prior to reperfusion, whereas it is likely
that no delay occurred in the “no treatment” arm (a
delay in the control arm would be, indeed, difﬁcult to
justify ethically) (51). As such, there are 2 differences
between the initial phase II study and the CYCLE: 1) a
>10-min delay compared with a 5-min delay; and 2) in
the initial phase II study there may have been an
intentional delay in the control group (favoring the
CsA arm), less likely to have occurred in the CYCLE
study.
The CIRCUS study, a larger double-blinded phase
III study, would not have been able to accommodate
a delay in PCI, and hence CsA was given shortly
before reperfusion, thus jeopardizing the efﬁcacy of
the CsA treatment (on the basis of the data derived
from pre-clinical studies). The exquisite dose-
dependent and time-dependent efﬁcacy of CsA pre-
sents a unique challenge to the performance of a
clinical trial. Indeed, having both a 10-min pre-
treatment or delay to allow for optimal CsA distri-
bution and no delay in the control arm to prevent
harm from delaying reperfusion is virtually impos-
sible in a double-blinded clinical trial. As such, an
open-label design with PROBE trial endpoint assess-
ment, as in the CYCLE study, but with a clearly
speciﬁed treatment delay of 10 min in the CsA arm
and no delay in the control arm, would be advisable,
with the understanding that this model was never
tested in pre-clinical studies. In the animal models,
CsA was given 10 min before reperfusion, but not
at the cost of prolonging ischemia; therefore, both
arms had the same duration of ischemia. In the
clinical setting, either a shift would be made such
that CsA is given before angiography, or it must
necessarily prolong ischemia by 10 min in the CsA
arm. Therefore, a question that could be tested in
animal models would be whether extending ischemia
to allow for CsA steady states is superior to immedi-
ate reperfusion.As outlined in Table 3, though promising, CsA did
not show all the characteristics of an ideal drug for
bench-to-bedside clinical translation.
Moreover, in this review we focused on potential
explanations for failure to translation for this class of
drug addressing speciﬁcally what is characteristic of
this class and not discussing other factors that are
common to the entire ﬁeld of ischemia-reperfusion
injury studies. First, the process of an AMI in
humans profoundly differs from that in experimental
animals: in pre-clinical settings, ischemia or reper-
fusion is performed using a speciﬁc coronary occluder
localized to a speciﬁc segment of a coronary artery
whereas in humans, the coronary occlusion may
occur anywhere in the coronary circulation and may
be acute and complete (100%) or gradual and
incomplete, or intermittent by undergoing several
occlusion or reperfusion episodes which may signiﬁ-
cantly change the signaling in the myocardium and
potentially the response to drug(s). Moreover, the
duration of coronary occlusion may vary widely in
humans whereas it is always precise in pre-clinical
studies. Second, the process of re-establishing coro-
nary blood ﬂow in humans is different than in ani-
mals: in the latter, the “complete” occlusion is
removed with precision and at a very speciﬁc time
point after occlusion, and invariably full reperfusion
is guaranteed, whereas in humans, the reperfusion is
established via medications, guidewires, balloons, or
stents. Each of these reperfusion modes can itself
limit reperfusion and in some cases embolization
with obstruction of the ﬂow downstream, conditions
that cannot be reproduced in the pre-clinical study.
Third, animal experiments are classically character-
ized by homogeneity of the cases and, in general, lack
of comorbidities, whereas humans with AMI classi-
cally have heterogeneous clinical conditions with
many comorbidities (i.e., diabetes, hypertension),
which may affect signaling and efﬁcacy of the drug(s).
Moreover, patients with AMI are generally treated
with multiple medications or treatments and the
novel strategy is tested on top of the standard of care,
whereas in pre-clinical research the novel strategy is
generally tested against an inactive treatment or no
treatment at all. These and other factors may explain
why drugs or treatments that are promising in pre-
clinical studies may fail in clinical trials (62).
CONCLUSIONS
Reperfusion injury limits the beneﬁt of reperfusion;
thus, prevention of this process is a potentially
valuable therapeutic target. Despite some encour-
aging pre-clinical data with CsA and other
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534mitochondrial membrane permeability inhibitors, the
overall results show inconsistent efﬁcacy of the in-
hibitors across different animal models and exquisite
dose- and time-dependent limitations. The phase II
clinical trials with CsA in AMI also showed inconsis-
tent results, possibly related to differences in study
design. Finally, a phase III study with CsA given with
reperfusion in patients with STEMI failed to provide
clinically signiﬁcant beneﬁts. Similar challenges have
been seen with 2 other drugs targeting the mito-
chondria (TRO40303 and MTP-131). To improve on
the ability to translate novel concepts and therapies
from bench to bedside, it is necessary that the pre-
clinical studies are designed, conducted, and inter-
preted with future clinical trials in mind, should
those tested interventions show promising results.
Clinical relevance of any beneﬁt must always be
considered, even in pre-clinical settings. On the other
hand, clinical trialists must also carefully review all
available pre-clinical data, and that phase III clinical
trials should be on the basis of the careful reviewed
data obtained from phase II studies, to assure that thelarger studies are adequately designed to test the
current understanding of any intervention and thus
optimize the chances of success for the treatment,
and ultimately determine whether the beneﬁcial ef-
fects on surrogate endpoints seen in phase II trials
translates in a reduction in adverse clinical events in
phase III trials. For CsA and other mitochondrial
membrane permeability inhibitors, timing of treat-
ment appears to be a fundamental determinant, To
what extent this applies to other classes of drugs or
treatments aimed at reducing ischemia-reperfusion
injury is, however, unknown.
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